Biofrontera AG
BFFTF
Other OTC0.33
USD
-6.60
- -
CIK
0001712641
ISIN
DE0006046113
Return %
Stock
S&P500
1Y
-75.56
18.99
3Y
-90.54
64.75
5Y
-95.48
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Pilar de la Huerta Martinez
- Full Time Employees
- 97
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Hemmelrather Weg 201 Leverkusen Germany 51377
- IPO Date
- Aug 24, 2018
- CIK
- 0001712641
- Website
- biofrontera.com
- Similar Companies
- Business
- Biofrontera AG operates as a biopharmaceutical firm, dedicating its efforts to the research, development, and commercialization of dermatological treatments. Its primary pharmaceutical offering is Ameluz, a topical medication, used in conjunction with its proprietary light-emitting diode (LED) devices, the BF-RhodoLED and the larger BF-RhodoLED XL lamps, for photodynamic therapy. This drug-device combination targets superficial skin cancers and their precursors, such as mild to moderate actinic keratoses on the face and scalp. While Biofrontera AG holds the patents and approvals for Ameluz and its associated lamps, it has strategically divested its United States assets related to Ameluz and RhodoLED to Biofrontera Inc. in October 2025, from which it now receives royalty payments on US sales. The company continues its direct market engagement across Europe, distributing Ameluz and its Belixos dermocosmetics range for irritated and sensitive skin. Recent activities include new agreements for Ameluz distribution in Croatia and partnerships to promote other dermatological brands within Germany. Biofrontera AG, founded in 1997, is headquartered in Leverkusen, Germany.